The economics of outsourcing highly potent molecules has always required careful decisionmaking, but even more so with today’s pipeline that includes less “blockbuster” type drugs and more “niche” or targeted molecules.
New approaches to production decisions are needed in order to balance revenue from smaller patient populations with the cost of complex manufacturing processes that must adhere to stringent safety and regulatory requirements.
This complimentary webinar from Baxter BioPharma Solutions provides insight on:
Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.